"Benzimidazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a BENZENE fused to IMIDAZOLES.
Descriptor ID |
D001562
|
MeSH Number(s) |
D03.633.100.103
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzimidazoles".
Below are MeSH descriptors whose meaning is more specific than "Benzimidazoles".
This graph shows the total number of publications written about "Benzimidazoles" by people in this website by year, and whether "Benzimidazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 1 | 1 | 2 |
2005 | 0 | 1 | 1 |
2011 | 1 | 0 | 1 |
2012 | 1 | 0 | 1 |
2013 | 1 | 1 | 2 |
2014 | 2 | 1 | 3 |
2016 | 5 | 0 | 5 |
2017 | 26 | 21 | 47 |
2018 | 31 | 12 | 43 |
2019 | 10 | 9 | 19 |
2020 | 1 | 0 | 1 |
2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Benzimidazoles" by people in Profiles.
-
Efficacy and safety of sofosbuvir plus daclatasvir or ravidasvir in patients with COVID-19: A randomized controlled trial. J Med Virol. 2021 12; 93(12):6750-6759.
-
Repurposing nonnucleoside antivirals against SARS-CoV2 NSP12 (RNA dependent RNA polymerase): In silico-molecular insight. Biochem Biophys Res Commun. 2021 09 24; 571:26-31.
-
Relatively mild symptoms after chronic overdose with a double-dose encorafenib: a case report. Anticancer Drugs. 2021 06 01; 32(5):589-591.
-
Candesartan as a tentative treatment for COVID-19: A prospective non-randomized open-label study. Int J Infect Dis. 2021 Jul; 108:159-166.
-
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat? Clin Sci (Lond). 2021 04 30; 135(8):1009-1014.
-
Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication. Cells. 2021 04 29; 10(5).
-
[Long-term efficacy of encorafenib plus binimetinib combined treatment: case report.] Recenti Prog Med. 2021 04; 112(4):49e-52e.
-
Neutralization of the eye and skin irritant benzalkonium chloride using UVC radiation. Cutan Ocul Toxicol. 2021 Jun; 40(2):78-84.
-
Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors. Proc Natl Acad Sci U S A. 2021 02 23; 118(8).
-
Reply to Ma and Wang: Reliability of various in vitro activity assays on SARS-CoV-2 main protease inhibitors. Proc Natl Acad Sci U S A. 2021 02 23; 118(8).